Skip to Content

'
Sheeba Koshy Thomas, MD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2009 UT School of Medicine, Houston, TX, MS, Clinical Research
1999 Boston University, Boston, MA, BA, Medical Sciences
1999 Boston University, Boston, MA, MD, Medicine

Postgraduate Training

7/2002-6/2005 Clinical Fellowship, Medical Oncology and Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, Robert A. Wolff, M.D.
6/1999-6/2002 Clinical Residency, Internal Medicine, Temple University Hospital, Philadelphia, PA, Richard S. Eisenstadt, M.D.

Board Certifications

2005 American Board of Internal Medicine, Medical Oncology, Recertification Date: 2025
10/2006 American Board of Internal Medicine, Hematology, Recertification Date: 2016
2002 American Board of Internal Medicine, Internal Medicine

Experience/Service

Academic Appointments

Clinical Specialist, Department of Internal Medicine, Division of Internal Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX, 8/2002-6/2005

Institutional Committee Activities

Member, Committee on Guidelines for Chemotherapy-induced Nausea and Vomiting, 9/2007-present
Member, Clinical Ethics Committee, 9/2007-8/2009
Member, Clinical Research Committee, 7/2006-8/2011

Honors and Awards

2004 Young Investigator Award, American Society of Clinical Oncology
2003 Aventis Award, Department of Thoracic Head & Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center
2003 Jesse H. Jones Clinical Research Fellowship Award, University of Texas M.D. Anderson Cancer Center
1999 Bachelor of Arts, magna cum laude, Boston University
1996 Summer Fellowship Grant, American Society of Hematology
1995 Dean's List, Boston University
1994 Golden Key National Honor Society, National Honor Society
1992-1995 University Scholar, Boston University

Professional Memberships

American Society of Clinical Oncology
Member, 2003-present
American Society of Hematology
Member, 2006-present
Harris County Medical Society, Houston, TX
Member, 2007-present
Massachusetts Medical Society, MA
Member, 1995-present
Southwest Oncology Group
Member, 2007-present
Texas Medical Association, TX
Member, 2007-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, Li X, Shah JJ, Gustafson SA, Weber DM, Miranda RN, Xu-Monette ZY, Orlowski RZ, Young KH. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma 23(5):1-10, 5/2016. e-Pub 12/2015. PMID: 26421453.
2. Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DL, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell 29(5):639-52, 5/2016. e-Pub 4/2016. PMID: 27132469.
3. Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Systemic Light chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. Eur J Haematol. e-Pub 1/16/2016. PMID: 26773409.
4. Mahale P, Thomas SK, Kyvernitakis A, Torres HA. Management of Multiple Myeloma Complicated by Hepatitis C Virus Reactivation: The Role of New Antiviral Therapy. Open Forum Infect Dis 3(1):ofv211, 1/2016. e-Pub 12/2015. PMCID: PMC4751339.
5. Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 16(1):36-42, 1/2016. e-Pub 12/2015. PMID: 26702475.
6. Alfaraj WA, Cachia D, Tummala S, Thomas SK, Manasanch EE. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia. Ann Hematol 95(2):347-8, 1/2016. e-Pub 10/2015. PMID: 26432713.
7. Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J 6:e396, 2016. e-Pub 2/2016. PMCID: PMC4771967.
8. Mendoza TR, Wang XS, Williams LA, Shi Q, Vichaya EG, Dougherty PM, Thomas SK, Yucel E, Bastida CC, Woodruff JF, Cleeland CS. Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale. J Pain 16(10):1032-43, 10/2015. e-Pub 7/2015. PMCID: PMC4592444.
9. Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström's Macroglobulinemia. Clin Cancer Res 21(11):2538-45, 6/2015. e-Pub 3/2015. PMCID: PMC4737551.
10. Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, Thomas SK, Shan J, Li S, Qazilbash M, Yin CC, Weber D, Miranda RN, Xu-Monette ZY, Medeiros LJ, Young KH. Waldenstrom macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol 8:74, 2015. e-Pub 6/2015. PMCID: PMC4487966.
11. Kosturakis AK, He Z, Li Y, Boyette-Davis JA, Shah N, Thomas SK, Zhang H, Vichaya EG, Wang XS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Cleeland CS, Dougherty PM. Subclinical Peripheral Neuropathy in Patients With Multiple Myeloma Before Chemotherapy Is Correlated With Decreased Fingertip Innervation Density. J Clin Oncol 32(28):3156-62, 10/2014. e-Pub 8/2014. PMCID: PMC4171359.
12. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 28(2):373-83, 2/2014. e-Pub 6/2013. PMCID: PMC3874423.
13. Thomas SK, Suvorov A, Noens L, Rukavitsin O, Fay J, Wu KL, Zimmerman TM, van de Velde H, Bandekar R, Puchalski TA, Qi M, Uhlar C, Samoylova OS. Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. Cancer Chemother Pharmacol 73(1):35-42, 1/2014. e-Pub 10/2013. PMID: 24149943.
14. Vichaya EG, Wang XS, Boyette-Davis JA, Mendoza TR, He Z, Thomas SK, Shah N, Williams LA, Cleeland CS, Dougherty PM. Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. Cancer Chemother Pharmacol 71(6):1531-40, 6/2013. e-Pub 3/2013. PMCID: PMC3669643.
15. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 161(3):357-66, 5/2013. e-Pub 2/2013. PMID: 23432640.
16. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. e-Pub 4/2013. PMID: 23545991.
17. Jones D, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK, Johnson VE, Champlin RE, Cleeland CS, Mendoza TR. Validation of the M.S. Anderson sympton inventory multiple myeloma module. J Hematol Oncol 6:13, 2013. e-Pub 2/2013. PMCID: PMC3598689.
18. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120(16):3260-70, 10/2012. e-Pub 8/2012. PMCID: PMC3476538.
19. Mendoza TR, Koyyalagunta D, Burton AW, Thomas SK, Phan MH, Giralt SA, Shah JJ, Cleeland CS. Changes in pain and other symptoms in patients with painful multiple myeloma-related vertebral fracture treated with kyphoplasty or vertebroplasty. J Pain 13(6):564-70, 6/2012. e-Pub 4/2012. PMCID: PMC3367066.
20. Thomas SK, Kwak LW. Lymphoma Vaccine Therapy: Next Steps After a Positive, Controlled Phase III Clinical Trial. Semin Oncol 39(3):253-62, 6/2012. PMID: 22595048.
21. Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H, Lin H, Lan Y, Liu Z, He J, Hong S, Thomas S, Shah J, Baladandayuthapani V, Kwak LW, Yi Q. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) 90(6):695-706, 6/2012. e-Pub 12/2011. PMID: 22207485.
22. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 3/2012. e-Pub 1/2012. PMID: 22231283.
23. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplant in patients aged 70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 1/2012. e-Pub 8/2011. PMID: 21780997.
24. Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BS. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer 117(19):4468-74, 10/2011. e-Pub 3/2011. PMID: 21437886.
25. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 152(5):579-92, 3/2011. e-Pub 1/2011. PMCID: PMC3402914.
26. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene 30(11):1329-40, 3/2011. e-Pub 11/2010. PMID: 21057542.
27. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling. Cancer Epidemiol Biomarkers Prev 19(10):2445-52, 10/2010. e-Pub 8/2010. PMCID: PMC2966770.
28. Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, Handy B, Lee JJ, Alexanian R. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant 45(3):498-504, 3/2010. e-Pub 7/2009. PMID: 19633690.
29. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):713-723, 6/2009. e-Pub 4/8/2009. PMCID: PMC4352933.
30. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with Gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-331, 2006. PMID: 16640804.

Invited Articles

1. Thomas S, Alexanian R. Current treatment strategies for multiple myeloma. Clin Lymphoma Myeloma 7 Suppl 4:S139-44, 2007. PMID: 17562251.
2. Thomas SK, Richards TA, Weber DM. Lenalidomide in multiple myeloma. Best Pract Res Clin Haematol 20(4)(4):717-735, 2007. PMID: 18070715.
3. Shah JJ, Orlowski RZ, Thomas SK. Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther Clin Risk Manag 5(1):151-159, 2/2009. e-Pub 3/2009. PMCID: PMC2697512.
4. Thomas SK, Richards TA, Weber DM. Novel agents for relapsed and/or refractory multiple myeloma. Cancer 15(6):485-93, 11/2009.

Abstracts

1. Hu B, Sasaki K, Bashir Q, Shah N, Patel KK, Popat UR, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen JL, Shah JJ, Manasanch EE, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Depth of response post autologous hematopoietic stem cell transplantation (auto-HCT) to predict outcome in high risk multiple myeloma (MM). J Clin Oncol 34, 6/2016.
2. Wang Y, Wagner-Bartak N, Zhou S, Fowler N, Dela Rosa ML, Zhao D, Romaguera JE, Neelapu SS, Hagemeister FB, Fanale MA, Oki Y, Shah JJ, Thomas SK, Hosing CM, Zhang L, Badillo M, Chen W, Cai Q, Zou D, Champlin RE, Fayad LE, Lee HJ, Michael Wang. Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial. Blood 126(23):3969, 12/2015.
3. Sasaki K, Shah N, Bashir Q, Hosing CM, Popat UR, Nieto Y, Parmar S, Shah JJ, Weber D, Weissinger D, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant. Blood 126(23):3194, 12/2015.
4. Shah JJ, Feng L, Thomas SK et al. Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood 126(23), 12/2015.
5. Shah JJ, Feng L, Weber D, Thomas SK, Wang M, Turturro F, Qazilbash MH, Shah N, Bashir Q, Popat UR, Manasanch EE, Munoz SC, Landry A, MendozaK, Nieto Y, Champlin RE, Orlowski RZ. Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood 126(23):3155, 12/2015.
6. Nooka AK, Wang M, Yee AJ, Thomas SK, O'Donnell EK, Shah JJ, Kaufman JL, Lonial S, Richardson PG, Raje NS. Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood 126(23):4246, 12/2015.
7. Claussen CM, Chuang T, Jatin Shah, Lee H, Shah N, Patel KK, Bashir Q, Parmar S, Thomas S, Qazilbash M, Davis RE, Neelapu SS, Weber D, Orlowski RZ, Feng L, Manasanch EE. Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. Blood 126(23):5390, 12/2015.
8. Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, Garcıa-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP. Treatment recommendations for patients with Waldenstrom¨ macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 124(21), 12/2014.
9. Ocio EM, Thomas SK, Günther A, Lebovic D, Kumar SK, Jakubowiak AJ, Song D, Ziang F, Hynds D, Vanase KG, Goh YT. Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma. Blood 122(21), 12/2013.
10. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a Role for CD44 and Cell Adhesion in Mediating Resistance to Lenalidomide in Multiple Myeloma: Therapeutic Implications. Leukemia. e-Pub 6/2013. PMID: 23760401.
11. Thomas SK, Haygood TM, Qazilbash MH, Melendez A, Galvis R, Delasalle KB, Feng L, Richards TA, Samaniego F, Wang L, Shah JJ, Orlowski RZ, Weber DM. A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM). Blood 122(21) (#4396), 2013.
12. Alagappan A, Shah R, Thomas SK, Weber DM, Wang M, Alexanian R, Orlowski RZ, Shah JJ. Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib. Blood 122(21), 2013.
13. Shah, JJ, Baladandayuthapani V, Weber DM, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Champlin RE, Shah N, Bashir Q, Popat UR, Nieto Y, Ahmed S, Parmar S, Orlowski RZ. Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma. Blood 122(21) (#1983), 2013.
14. Treon SP, Tripsas CK, Meid K, Patterson C, Heffner LT, Eradat H, Gregory SA, Thomas SK, Advani RH, Baz R, Badros AZ, Matous J, Murphy TJ, Ghobrial IM. Prospective, Multicenter Study Of The Mtor Inhibitor Everolimus (RAD001) As Primary Therapy In Waldenstrom’s Macroglobulinemia. Blood 122(21), 2013.
15. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120(21), 12/2012.
16. Vichaya EG, Wang S, Boyette-Davis JA, Thomas SK, Shah N, Mendoza TR, Williams LA, Cleeland CS, Dougherty PM. Baseline subclinical sensory deficits and the development of pain and numbness in patients with multiple myeloma (MM) being treated with chemotherapy. J Clin Oncol 30 (#9082), 2012.
17. Thomas SK, Mendoza TR, Vichaya EG, Wang XS, Sailors MH, Williams LA, Dougherty PM, Cleeland CS. Validation of the chemotherapy-induced neuropathy assessment scale. J Clin Oncol 30 (#9140), 2012.
18. Thomas SK. ISSMM and IPSSWM as Prognosticators in WM. Venice, Italy, 2010. 6th International Workshop on Waldenstrom's Macroglobulinemia Venice, 2010.
19. Voorhees PM, Manges RF, Somio G, Lentzsch S, Jagannath S, Sonneveld P, Frank RC, Zweegman S, Wijermans PW, Thomas S. A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM). J Clin Oncol 27(15s) (#8527), 2009.
20. Delasalle KB, Wang L, Weber D, Giralt SA, Thomas S, Shah J, Handy B, Orlowski RZ, Alexanian R. Curability of Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 114:3864, 2009.
21. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Korbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, Marcos D, Weber DM, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Blood 15(6):718-23, 2009. PMID: 19450756.
22. Thomas S, Feng L, Delasalle KB, Wang M, Shah JJ, Orlowski RZ, Alexanian R, Weber DM. Prognostic Factors for survival after 2-CdA-based therapy for symptomatic Waldenstrom Macroglobulinemia (WM) stratify patients into low- and high-risk groups. Blood (ASH Annual Meeting Abstracts) 114:1668, 2009.
23. Shah N, Weber D, Orlowski R, Wang M, Thomas SK, Richards T, Giralt S, Qazilbash M, Alexanian R and Shah JJ. Role of autologous stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients. J Clin Oncol 27(Suppl):15S (#8596), 2009.
24. Shah N, Weber DM, Wang M, Thomas S, Shah J, Giralt S, Alexanian R, Orlowski RZ, Qazilbash MH, and Avery T. Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation. Blood:1395, 2009.
25. Thomas S, Hosing C, Delasalle K, Gavino M, Popat U, Qazilbash M, Giralt S, Weber D, Alexanian R. Success rates of autologous stem cell collection in patients with Waldenstrom Macroglobulinemia. 5th International Workshop on Waldenstrom's Macroglobulinemia Stockholm. Sweden 2008, 2008.

Book Chapters

1. Thomas S, Wang M, Weber D. Abnormal serum protein electrophoresis. In: Decision Making in Medicine, An Algorithmic Approach. Mosby, Inc: Philadelphia, 2010.
2. Thomas S, Richards T, Weber DM. Lenalidomide in relapsed or refractory multiple myeloma. In: Myeloma Myeloma Therapy: Pursuing the Plasma Cell (Contemporary Hematology). Ed(s) S Lonial. The Humana Press, Inc. Totowa, NJ, 2008.
3. Thomas S, Richards T, Weber DM. Novel agents for previously untreated multiple myeloma. In: Multiple Myeloma. Ed(s) I. Ghobrial, M.D., K. Anderson, M.D. Informa Healthcare: New York, 2008.

Manuals, Teaching Aids, Other Teaching Publications

1. Thomas S. Multiple Myeloma: Questions and Answers. M.D. Anderson Cancer Center: Houston, 2005.

Grant & Contract Support

Title: M.D. Anderson Cancer Center SPORE in Multiple Myeloma, Project 2
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 9/22/2010 - 8/31/2015
 
Title: Chemokine-Idiotype DNA Fusion Vaccines as a Therapeutic Anti-Tumor Strategy for Lymphoplasmacytic Lymphoma, Multiple Myeloma SPORE Grant Career Development Program
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2010 - 8/31/2012
 
Title: Translational Development of Novel Lymphoma Vaccines
Funding Source: CPRIT
Role: Co-Investigator
Duration: 5/1/2010 - 4/30/2013
 
Title: Mechanisms of Symptoms of Multiple Myeloma and Its Therapy, Prevention of Treatment Induced Neuropathy in Patients with Multiple Myeloma
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Charles Cleeland
Duration: 9/1/2008 - 8/30/2013
 
Title: Database of Patients with Plasma Cell Dyscrasias
Funding Source: M D Anderson Cancer Center
Role: Principal Investigator
Duration: 9/6/2006 - 9/6/2009

Last updated: 8/25/2016